Cargando…

Clinical, Virological and Immunological Subphenotypes in a Cohort of Early Treated HIV-Infected Children

BACKGROUND: Identifying subphenotypes within heterogeneous diseases may have an impact in terms of therapeutic options. In this study, we aim to assess different subphenotypes in children living with human immunodeficiency virus (HIV-1), according to the clinical, virological, and immunological char...

Descripción completa

Detalles Bibliográficos
Autores principales: Domínguez-Rodríguez, Sara, Tagarro, Alfredo, Foster, Caroline, Palma, Paolo, Cotugno, Nicola, Zicari, Sonia, Ruggiero, Alessandra, de Rossi, Anita, Dalzini, Annalisa, Pahwa, Savita, Rinaldi, Stefano, Nastouli, Eleni, Marcelin, Anne-Geneviève, Dorgham, Karim, Sauce, Delphine, Gartner, Kathleen, Rossi, Paolo, Giaquinto, Carlo, Rojo, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111748/
https://www.ncbi.nlm.nih.gov/pubmed/35592310
http://dx.doi.org/10.3389/fimmu.2022.875692
_version_ 1784709301724512256
author Domínguez-Rodríguez, Sara
Tagarro, Alfredo
Foster, Caroline
Palma, Paolo
Cotugno, Nicola
Zicari, Sonia
Ruggiero, Alessandra
de Rossi, Anita
Dalzini, Annalisa
Pahwa, Savita
Rinaldi, Stefano
Nastouli, Eleni
Marcelin, Anne-Geneviève
Dorgham, Karim
Sauce, Delphine
Gartner, Kathleen
Rossi, Paolo
Giaquinto, Carlo
Rojo, Pablo
author_facet Domínguez-Rodríguez, Sara
Tagarro, Alfredo
Foster, Caroline
Palma, Paolo
Cotugno, Nicola
Zicari, Sonia
Ruggiero, Alessandra
de Rossi, Anita
Dalzini, Annalisa
Pahwa, Savita
Rinaldi, Stefano
Nastouli, Eleni
Marcelin, Anne-Geneviève
Dorgham, Karim
Sauce, Delphine
Gartner, Kathleen
Rossi, Paolo
Giaquinto, Carlo
Rojo, Pablo
author_sort Domínguez-Rodríguez, Sara
collection PubMed
description BACKGROUND: Identifying subphenotypes within heterogeneous diseases may have an impact in terms of therapeutic options. In this study, we aim to assess different subphenotypes in children living with human immunodeficiency virus (HIV-1), according to the clinical, virological, and immunological characteristics. METHODS: We collected clinical and sociodemographic data, baseline viral load (VL), CD4 and CD8 count and percentage, age at initiation of ART, HIV DNA reservoir size in peripheral blood mononuclear cells (PBMCs), cell-associated RNA (CA-RNA), ultrasensitive VL, CD4 subsets (T effector CD25+, activated memory cells, Treg cells), humoral-specific HIV response (T-bet B cells), innate response (CD56dim natural killer (NK) cells, NKp46+, perforin), exhaustion markers (PD-1, PD-L1, DNAM), CD8 senescence, and biomarkers for T-lymphocyte thymic output (TREC) and endothelial activation (VCAM). The most informative variables were selected using an unsupervised lasso-type penalty selection for sparse clustering. Hierarchical clustering was performed using Pearson correlation as the distance metric and WARD.D2 as the clustering method. Internal validation was applied to select the best number of clusters. To compare the characteristics among clusters, boxplot and Kruskal Wallis test were assessed. RESULTS: Three subphenotypes were discovered (cluster1: n=18, 45%; cluster2: n=11, 27.5%; cluster3: n=11, 27.5%). Patients in cluster1 were treated earlier, had higher baseline %CD4, low HIV reservoir size, low western blot score, higher TREC values, and lower VCAM values than the patients in the other clusters. In contrast, cluster3 was the less favorable. Patients were treated later and presented poorer outcomes with lower %CD4, and higher reservoir size, along with a higher percentage of CD8 immunosenescent cells, lower TREC, higher VCAM cytokine, and a higher %CD4 PD-1. Cluster2 was intermediate. Patients were like those of cluster1, but had lower levels of t-bet expression and higher HIV DNA reservoir size. CONCLUSIONS: Three HIV pediatric subphenotypes with different virological and immunological features were identified. The most favorable cluster was characterized by a higher rate of immune reconstitution and a slower disease progression, and the less favorable with more senescence and high reservoir size. In the near future therapeutic interventions for a path of a cure might be guided or supported by the different subphenotypes.
format Online
Article
Text
id pubmed-9111748
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91117482022-05-18 Clinical, Virological and Immunological Subphenotypes in a Cohort of Early Treated HIV-Infected Children Domínguez-Rodríguez, Sara Tagarro, Alfredo Foster, Caroline Palma, Paolo Cotugno, Nicola Zicari, Sonia Ruggiero, Alessandra de Rossi, Anita Dalzini, Annalisa Pahwa, Savita Rinaldi, Stefano Nastouli, Eleni Marcelin, Anne-Geneviève Dorgham, Karim Sauce, Delphine Gartner, Kathleen Rossi, Paolo Giaquinto, Carlo Rojo, Pablo Front Immunol Immunology BACKGROUND: Identifying subphenotypes within heterogeneous diseases may have an impact in terms of therapeutic options. In this study, we aim to assess different subphenotypes in children living with human immunodeficiency virus (HIV-1), according to the clinical, virological, and immunological characteristics. METHODS: We collected clinical and sociodemographic data, baseline viral load (VL), CD4 and CD8 count and percentage, age at initiation of ART, HIV DNA reservoir size in peripheral blood mononuclear cells (PBMCs), cell-associated RNA (CA-RNA), ultrasensitive VL, CD4 subsets (T effector CD25+, activated memory cells, Treg cells), humoral-specific HIV response (T-bet B cells), innate response (CD56dim natural killer (NK) cells, NKp46+, perforin), exhaustion markers (PD-1, PD-L1, DNAM), CD8 senescence, and biomarkers for T-lymphocyte thymic output (TREC) and endothelial activation (VCAM). The most informative variables were selected using an unsupervised lasso-type penalty selection for sparse clustering. Hierarchical clustering was performed using Pearson correlation as the distance metric and WARD.D2 as the clustering method. Internal validation was applied to select the best number of clusters. To compare the characteristics among clusters, boxplot and Kruskal Wallis test were assessed. RESULTS: Three subphenotypes were discovered (cluster1: n=18, 45%; cluster2: n=11, 27.5%; cluster3: n=11, 27.5%). Patients in cluster1 were treated earlier, had higher baseline %CD4, low HIV reservoir size, low western blot score, higher TREC values, and lower VCAM values than the patients in the other clusters. In contrast, cluster3 was the less favorable. Patients were treated later and presented poorer outcomes with lower %CD4, and higher reservoir size, along with a higher percentage of CD8 immunosenescent cells, lower TREC, higher VCAM cytokine, and a higher %CD4 PD-1. Cluster2 was intermediate. Patients were like those of cluster1, but had lower levels of t-bet expression and higher HIV DNA reservoir size. CONCLUSIONS: Three HIV pediatric subphenotypes with different virological and immunological features were identified. The most favorable cluster was characterized by a higher rate of immune reconstitution and a slower disease progression, and the less favorable with more senescence and high reservoir size. In the near future therapeutic interventions for a path of a cure might be guided or supported by the different subphenotypes. Frontiers Media S.A. 2022-05-03 /pmc/articles/PMC9111748/ /pubmed/35592310 http://dx.doi.org/10.3389/fimmu.2022.875692 Text en Copyright © 2022 Domínguez-Rodríguez, Tagarro, Foster, Palma, Cotugno, Zicari, Ruggiero, de Rossi, Dalzini, Pahwa, Rinaldi, Nastouli, Marcelin, Dorgham, Sauce, Gartner, Rossi, Giaquinto and Rojo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Domínguez-Rodríguez, Sara
Tagarro, Alfredo
Foster, Caroline
Palma, Paolo
Cotugno, Nicola
Zicari, Sonia
Ruggiero, Alessandra
de Rossi, Anita
Dalzini, Annalisa
Pahwa, Savita
Rinaldi, Stefano
Nastouli, Eleni
Marcelin, Anne-Geneviève
Dorgham, Karim
Sauce, Delphine
Gartner, Kathleen
Rossi, Paolo
Giaquinto, Carlo
Rojo, Pablo
Clinical, Virological and Immunological Subphenotypes in a Cohort of Early Treated HIV-Infected Children
title Clinical, Virological and Immunological Subphenotypes in a Cohort of Early Treated HIV-Infected Children
title_full Clinical, Virological and Immunological Subphenotypes in a Cohort of Early Treated HIV-Infected Children
title_fullStr Clinical, Virological and Immunological Subphenotypes in a Cohort of Early Treated HIV-Infected Children
title_full_unstemmed Clinical, Virological and Immunological Subphenotypes in a Cohort of Early Treated HIV-Infected Children
title_short Clinical, Virological and Immunological Subphenotypes in a Cohort of Early Treated HIV-Infected Children
title_sort clinical, virological and immunological subphenotypes in a cohort of early treated hiv-infected children
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111748/
https://www.ncbi.nlm.nih.gov/pubmed/35592310
http://dx.doi.org/10.3389/fimmu.2022.875692
work_keys_str_mv AT dominguezrodriguezsara clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT tagarroalfredo clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT fostercaroline clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT palmapaolo clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT cotugnonicola clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT zicarisonia clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT ruggieroalessandra clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT derossianita clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT dalziniannalisa clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT pahwasavita clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT rinaldistefano clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT nastoulieleni clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT marcelinannegenevieve clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT dorghamkarim clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT saucedelphine clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT gartnerkathleen clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT rossipaolo clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT giaquintocarlo clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren
AT rojopablo clinicalvirologicalandimmunologicalsubphenotypesinacohortofearlytreatedhivinfectedchildren